The Canadian Cancer Trials Group
@cctg.bsky.social
The Canadian Cancer Trials Group (CCTG) is an academic cooperative oncology group that designs and conducts clinical trials testing cancer therapy, supportive care and prevention interventions across Canada.
Congratulations to Dr. Shivani Dadwal on enrolling her first patient to the #CCTG CRC.10 trial as a new investigator! A 2024–2025 CCTG New Investigator Practicum graduate, Dr. Dadwal is advancing more personalized treatment for patients with colon cancer. buff.ly/waBXgf6
The #CCTG Quality of Life Committee is recruiting two new members with expertise or interest in patient-reported outcomes (PROs) in cancer clinical trials. Help advance patient-centered research in brain cancer or supportive care. Apply by August 31!#CancerResearch #ClinicalTrials buff.ly/cScBpnk
On #WorldHeadAndNeckCancerDay, we're highlighting the #CCTG HN11 trial evaluating whether lymphatic mapping can help personalize radiotherapy for oropharyngeal cancer while reducing side effects and improving quality of life. #HeadAndNeckCancer #ClinicalTrials
As Sarcoma Cancer Awareness Month comes to a close, we are highlighting #CCTG SR.7, a clinical trial for patients with high-risk retroperitoneal sarcoma studying whether chemotherapy before surgery can improve outcomes. #SarcomaAwareness
#CCTG continues to advance cancer research across Canada with new trials now open and more on the horizon. From hematologic cancers to breast, lung, sarcoma, and supportive care, our clinical trial portfolio is helping shape the future of cancer care. #ClinicalTrials #CancerResearch
#CCTG continues to advance cancer research across Canada with new trials now open and more on the horizon. From hematologic cancers to breast, lung, sarcoma, and supportive care, our clinical trial portfolio is helping shape the future of cancer care. #ClinicalTrials #CancerResearch
A new #CCTG clinical trial, SC31 TEMPO, is now open! This study is evaluating an innovative online program designed to help people with prostate cancer and their caregivers better manage the physical and emotional challenges of cancer. #ProstateCancer #CancerResearch buff.ly/oj7LzVq
During Sarcoma Cancer Awareness Month, we're highlighting #CCTG SRC.8, a clinical trial evaluating whether adding immunotherapy to chemotherapy can improve outcomes for patients with advanced sarcoma. #SarcomaAwarenessMonth #CureSarcoma
Two new #CCTG cell therapy trials are now open in Canada! IND246 is evaluating the novel #CAR-T therapy #GCAR1 in solid cancers, while IND245 is exploring strategies to improve #CAR-T outcomes for patients with mantle cell lymphoma. #CellTherapy #CancerResearch
The first two CCTG led cell therapy trials are now open in Canada | Canadian Cancer Trials Group
CCTG is committed to the evaluation of innovative cell therapy products, strategies to improve cell therapy outcomes and to advancing accessibility for Canadian patients. IND246 study is a phase I…
buff.ly
A new #CCTG clinical trial, LYC.2, has opened in Canada for patients with peripheral T-cell lymphoma (#PTCL)! This phase III study is evaluating whether high-dose chemotherapy followed by autologous stem cell transplant can reduce the risk of disease recurrence. #Lymphoma buff.ly/c8RMgOF
#CCTG is seeking a volunteer #CRA representative to join the Hematology Disease Site Committee! This is an opportunity to contribute to the oversight and development of cancer clinical trials in Canada. Applications close July 15, 2026. #ClinicalResearch #Hematology buff.ly/kxVcaT7
Today is Pride Day and #CCTG celebrates the strength, diversity, and contributions of 2SLGBTQIA+ communities. We remain committed to advancing inclusive cancer research and fostering environments where everyone feels seen, respected, and supported 🌈#PrideMonth #Pride2026
The @cctg.bsky.social, @eortc.org, and @amrc-uk.bsky.social welcome the #G7 Leaders’ announcement recognizing cancer as a global priority and calling for stronger international cooperation to improve outcomes for patients: buff.ly/lvBpd0V
Welcome Melanie Keats to #CCTG as the new Patient Representative for the Gynecology Disease Site Committee! Drawing on her experiences as a patient, caregiver, family member, and researcher, Melanie will ensure the patient voice remains central to cancer research. #PatientEngagment
Join the next #CCTG CRA Lunch and Learn session on Compliance Tips and CAPA Tricks This Friday June 24th! These practical training sessions provide valuable insight and resources to support the activation and conduct of CCTG studies. Register now for this practical training session. buff.ly/GTSqkMc
June 21 is National Indigenous Peoples Day. As part of CCTG’s commitment to reconciliation, we will continue to listen, learn, and identify how we can design clinical trials that are culturally safe and accessible for Indigenous peoples in Canada. #NIPD2026 #IndigenousPeoplesDay #CCTG
The #CCTG Quality of Life committee is seeking two new network members with an interest in #PROs in cancer clinical trials. Opportunities are focused on brain cancer and supportive care. Join us in advancing patient-centered cancer research! buff.ly/4mr3nmV #CancerResearch #PatientReportedOutcomes
#CCTG recognizes #CancerImmunotherapyMonth and the science transforming cancer treatment. A spotlight on the SRC8 trial, investigation if a combination of immunotherapy and chemotherapy is more effective than chemotherapy alone for adults with advanced sarcoma: buff.ly/FAA5dNE #Immune2Cancer
This June #CCTG marks both National Indigenous History Month and Pride Month. It is a time to learn about and honour the diverse cultures, histories, and experiences of First Nations, Inuit, and Métis Peoples, and to celebrate the strength, resilience, and contributions of 2SLGBTQI+ communities.
Applications are now open for the #CCTG 2026 New Investigator Training course (NITC)! This 2.5-day program equips Canadas next generation of cancer clinical trial investigators with the knowledge and skills needed to lead impactful research. #CancerResearch #ClinicalTrials buff.ly/Ij9U38k
A new #myeloMATCH clinical trial, #CCTG ALC10 has opened in Canada! Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy. buff.ly/ABTpHbj #Hematology #ClinicalTrials #BCCancer @swog.org
A groundbreaking study led by VCHRI researcher Dr. Lucia Nappi identified a blood biomarker that could help doctors predict the early-stage germ cell cancer relapse & begin active treatment sooner: buff.ly/wLDl01S @cctg.bsky.social
A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors | Canadian Cancer Trials Group
The interim results of the GCC.1 / S1823 study were presented at ASCO 2026 during the Genitourinary Cancer Session. The study focuses on patients with early-stage germ cell tumors and the blood…
ctg.queensu.ca
This $3,000 supervised exercise program drastically cuts colon cancer recurrence. Here’s why Canadian doctors say it should be prescribed and funded like a drug, by Megan Ogilvie www.thestar.com/news/canada/... via @thestar.com
This $3,000 program drastically cuts colon cancer recurrence. Doctors say it should be funded like a drug
Supervised exercise programs, which cost about $3,000 per patient over three years, boost survival rates and save the health system money, study shows.
thestar.com
#CCTG HN.9 results presented at #ASCO26, highlighting the challenges of reducing treatment intensity while maintaining outcomes for patients with HPV-positive oropharyngeal cancer-investigating whether replacing the standard chemotherapy with immunotherapy could reduce side effects. buff.ly/bj30GIR
A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @swog.org S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier Presented by #DrLuciaNappi buff.ly/wLDl01S @vchresearch.bsky.social
The #CCTG PR.21 secondary analysis presented at #ASCO26 explores treatment sequencing in advanced prostate cancer. Results support both therapies as treatment options and may help clinicians make more personalized treatment decisions based on patient preferences. buff.ly/DQLTfTB
Landmark CO.21 CHALLENGE #ASCO26 economic analysis shows that exercise programs can reduce health system costs. Dr Chen leading #CCTG researchers showed that structured exercise has positive outcomes for patients and at a lower cost than most treatment regimens. buff.ly/xQTzQVY
A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @swog.org S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier Presented by #DrLuciaNappi buff.ly/wLDl01S @vchresearch.bsky.social
CO26 poster presentation at #ASCO2026 - Serum VEGF-A concentrations as a predictive biomarker of immunotherapy response in refractory metastatic colorectal cancer (mCRC): An exploratory analysis of CCTG CO.26 www.asco.org/abstracts-pr...
